Acutus Medical Q2 2024 Earnings Results & Report

Acutus Medical EPS Results

• Actual EPS: -$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 5 of last 8 quarters

Acutus Medical Revenue Results

• Actual Revenue: $4.13 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Acutus Medical (NASDAQ:AFIB) was a medical device company focused on improving the diagnosis and treatment of cardiac arrhythmias, particularly atrial fibrillation. The company developed technologies intended to help electrophysiologists create detailed three-dimensional maps of the heart and guide catheter-based ablation procedures.

Its principal product was the AcQMap electrophysiology imaging and mapping system, which combined ultrasound-based imaging with electrical mapping to visualize cardiac anatomy and arrhythmia activity. The system was designed to support the identification of abnormal electrical signals and assist physicians in planning and performing ablation treatments. Acutus also developed associated mapping catheters, software and related procedural tools.

Founded in 2011 and headquartered in Carlsbad, California, Acutus marketed its products in the United States and select international markets, including Europe. The company completed its initial public offering on the Nasdaq under the symbol AFIB in 2020. In 2023, Acutus announced an agreement to sell substantially all of its assets to Medtronic, after which its standalone operations were wound down.